CryoPort (CYRX)
Market Price (7/5/2026): $15.51 | Market Cap: $773.9 MilSector: Industrials | Industry: Air Freight & Logistics
CryoPort (CYRX)
Market Price (7/5/2026): $15.51Market Cap: $773.9 MilSector: IndustrialsIndustry: Air Freight & Logistics
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.6% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. | Weak multi-year price returns3Y Excs Rtn is -82% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -39 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% Stock price has recently run up significantly12M Rtn12 month market price return is 108% Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.4% Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% Key risksCYRX key risks include [1] severe financial underperformance, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.8%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 5.6% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Megatrend and thematic driversMegatrends include Advanced Biologics Supply Chain. Themes include Cell and Gene Therapy Logistics, Cryogenic Cold Chain Management, and Biopharmaceutical Clinical Trial Support. |
| Weak multi-year price returns3Y Excs Rtn is -82% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -39 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -21% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 108% |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -5.4% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -14% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% |
| Key risksCYRX key risks include [1] severe financial underperformance, Show more. |
Qualitative Assessment
AI Analysis | Feedback
CryoPort (CYRX) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Exceeded Fiscal Q1 2026 Revenue Expectations and Increased Full-Year Guidance. CryoPort reported strong financial results for its fiscal Q1 2026 (ended March 31, 2026), with revenue reaching $47.8 million, a 16% increase year-over-year, surpassing analyst estimates of $45.76 million. Following this performance, the company raised its full-year revenue guidance to $192 million - $196 million.
2. Robust Growth in Commercial Cell and Gene Therapy (CGT) Segment. The company demonstrated significant momentum in the high-growth commercial cell and gene therapy (CGT) sector, with revenue from this segment increasing by 26% year-over-year to $9.1 million in fiscal Q1 2026. As of March 31, 2026, CryoPort was supporting a record 21 commercially approved CGTs and 766 global clinical trials, underscoring its critical role in this expanding market.
Show more
CryoPort (CYRX) stock has gained about 85% since 3/31/2026 because of the following key factors:
1. Exceeded Fiscal Q1 2026 Revenue Expectations and Increased Full-Year Guidance. CryoPort reported strong financial results for its fiscal Q1 2026 (ended March 31, 2026), with revenue reaching $47.8 million, a 16% increase year-over-year, surpassing analyst estimates of $45.76 million. Following this performance, the company raised its full-year revenue guidance to $192 million - $196 million.
2. Robust Growth in Commercial Cell and Gene Therapy (CGT) Segment. The company demonstrated significant momentum in the high-growth commercial cell and gene therapy (CGT) sector, with revenue from this segment increasing by 26% year-over-year to $9.1 million in fiscal Q1 2026. As of March 31, 2026, CryoPort was supporting a record 21 commercially approved CGTs and 766 global clinical trials, underscoring its critical role in this expanding market.
3. Favorable Analyst Sentiment and Upgraded Price Targets. Analyst sentiment significantly improved during the period, with a consensus rating shifting to "Strong Buy" or "Moderate Buy" from multiple firms. Several analysts upgraded their price targets for CYRX; notably, Craig-Hallum raised its target to $20.00 on June 3, 2026, while Keybanc increased its target to $17.00 on May 20, 2026. The average analyst price target ranged from $15.11 to $16.20.
4. Strategic Business Developments and Path to Profitability. CryoPort continued to expand its strategic footprint, including the announcement on June 25, 2026, that its IntegriCell® Cryopreservation Services were selected by Verismo Therapeutics to support clinical KIR-CAR T Cell Therapy Programs. Furthermore, the company maintained its expectation of achieving positive adjusted EBITDA in the second half of fiscal year 2026, which was a key driver of investor confidence.
Show less
Stock Movement Drivers
Fundamental Drivers
The 87.1% change in CYRX stock from 3/31/2026 to 7/4/2026 was primarily driven by a 83.3% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.28 | 15.49 | 87.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 176 | 183 | 3.8% |
| Net Income Margin (%) | 42.4% | 41.6% | -1.8% |
| P/E Multiple | 5.5 | 10.2 | 83.3% |
| Shares Outstanding (Mil) | 50 | 50 | 0.1% |
| Cumulative Contribution | 87.1% |
Market Drivers
3/31/2026 to 7/4/2026| Return | Correlation | |
|---|---|---|
| CYRX | 87.1% | |
| Market (SPY) | 14.5% | 31.9% |
| Sector (XLI) | 13.7% | 13.8% |
Fundamental Drivers
The 61.4% change in CYRX stock from 12/31/2025 to 7/4/2026 was primarily driven by a 42.7% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.60 | 15.49 | 61.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 172 | 183 | 6.2% |
| Net Income Margin (%) | 39.2% | 41.6% | 5.9% |
| P/E Multiple | 7.1 | 10.2 | 42.7% |
| Shares Outstanding (Mil) | 50 | 50 | 0.5% |
| Cumulative Contribution | 61.4% |
Market Drivers
12/31/2025 to 7/4/2026| Return | Correlation | |
|---|---|---|
| CYRX | 61.4% | |
| Market (SPY) | 9.5% | 43.5% |
| Sector (XLI) | 18.9% | 24.3% |
Fundamental Drivers
The 107.6% change in CYRX stock from 6/30/2025 to 7/4/2026 was primarily driven by a 82.0% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.46 | 15.49 | 107.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 161 | 183 | 14.0% |
| P/S Multiple | 2.3 | 4.2 | 82.0% |
| Shares Outstanding (Mil) | 50 | 50 | 0.1% |
| Cumulative Contribution | 107.6% |
Market Drivers
6/30/2025 to 7/4/2026| Return | Correlation | |
|---|---|---|
| CYRX | 107.6% | |
| Market (SPY) | 21.6% | 31.6% |
| Sector (XLI) | 26.0% | 22.4% |
Fundamental Drivers
The -10.2% change in CYRX stock from 6/30/2023 to 7/4/2026 was primarily driven by a -26.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7042026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.25 | 15.49 | -10.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 248 | 183 | -26.2% |
| P/S Multiple | 3.4 | 4.2 | 25.5% |
| Shares Outstanding (Mil) | 48 | 50 | -3.1% |
| Cumulative Contribution | -10.2% |
Market Drivers
6/30/2023 to 7/4/2026| Return | Correlation | |
|---|---|---|
| CYRX | -10.2% | |
| Market (SPY) | 74.0% | 31.5% |
| Sector (XLI) | 78.5% | 31.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CYRX Return | 35% | -71% | -11% | -50% | 23% | 65% | -64% |
| Peers Return | 33% | -35% | 4% | 11% | -1% | -6% | -7% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| CYRX Win Rate | 50% | 42% | 33% | 50% | 50% | 57% | |
| Peers Win Rate | 58% | 37% | 50% | 45% | 53% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| CYRX Max Drawdown | -41% | -73% | -65% | -71% | -47% | -31% | |
| Peers Max Drawdown | -28% | -53% | -43% | -32% | -40% | -33% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AZTA, BLFS, TMO, GTLS, RGEN. See CYRX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/2/2026 (YTD)
How Low Can It Go
| Event | CYRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.8% | -18.8% |
| % Gain to Breakeven | 46.6% | 23.1% |
| Time to Breakeven | 2 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.6% | -9.5% |
| % Gain to Breakeven | 74.3% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.8% | -33.7% |
| % Gain to Breakeven | 38.5% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -34.9% | -19.2% |
| % Gain to Breakeven | 53.6% | 23.8% |
| Time to Breakeven | 65 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -62.9% | -12.2% |
| % Gain to Breakeven | 169.2% | 13.9% |
| Time to Breakeven | 72 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -52.6% | -6.8% |
| % Gain to Breakeven | 111.1% | 7.3% |
| Time to Breakeven | 64 days | 15 days |
In The Past
CryoPort's stock fell -31.8% during the 2025 US Tariff Shock. Such a loss loss requires a 46.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CYRX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.8% | -18.8% |
| % Gain to Breakeven | 46.6% | 23.1% |
| Time to Breakeven | 2 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -42.6% | -9.5% |
| % Gain to Breakeven | 74.3% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.8% | -33.7% |
| % Gain to Breakeven | 38.5% | 50.9% |
| Time to Breakeven | 43 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -34.9% | -19.2% |
| % Gain to Breakeven | 53.6% | 23.8% |
| Time to Breakeven | 65 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -62.9% | -12.2% |
| % Gain to Breakeven | 169.2% | 13.9% |
| Time to Breakeven | 72 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -52.6% | -6.8% |
| % Gain to Breakeven | 111.1% | 7.3% |
| Time to Breakeven | 64 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -63.5% | -0.2% |
| % Gain to Breakeven | 174.3% | 0.2% |
| Time to Breakeven | 134 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -33.8% | -17.9% |
| % Gain to Breakeven | 51.0% | 21.8% |
| Time to Breakeven | 1376 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -51.1% | -15.4% |
| % Gain to Breakeven | 104.4% | 18.2% |
| Time to Breakeven | 1829 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -73.6% | -53.4% |
| % Gain to Breakeven | 278.8% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
CryoPort's stock fell -31.8% during the 2025 US Tariff Shock. Such a loss loss requires a 46.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CryoPort (CYRX)
CryoPort (CYRX) is a life sciences services company specializing in temperature-controlled logistics solutions. It primarily focuses on ensuring the safe and stable transportation and storage of sensitive biologic commodities, such as cells, tissues, and vaccines, across global markets. Essentially, CryoPort provides critical infrastructure and services for the handling of valuable biological materials, crucial for research, clinical trials, and commercial applications in the life sciences industry.
The company's offerings include its proprietary cloud-based logistics management platform, Cryoportal, which facilitates end-to-end shipment management from order to delivery, including real-time tracking and regulatory compliance. Complementing this are their specialized CryoPort Express Shippers, designed to maintain the integrity of biologics during transit, and the SmartPak Condition Monitoring System for data collection and validation. CryoPort also supplies vacuum insulated dewars and cryogenic freezers, alongside comprehensive services like biological specimen cryopreservation storage, archiving, monitoring, and transportation.
CryoPort serves a vital role for customers in high-stakes industries where the integrity of biological materials is paramount. Its primary markets include the biopharma and pharmaceutical sectors, supporting drug development and distribution; the animal health industry; and human reproductive medicine, ensuring the safe handling of genetic materials.
AI Analysis | Feedback
Here are 1-3 brief analogies for CryoPort (CYRX):
- Like a highly specialized FedEx or UPS, but exclusively for critical, temperature-sensitive biological materials.
- An Iron Mountain for frozen biological samples, coupled with a global, specialized delivery network.
AI Analysis | Feedback
- Cryoportal Platform: A cloud-based logistics management platform for order entry, documentation, real-time shipment tracking, and regulatory compliance.
- Temperature-Controlled Shipping Solutions: Specialized shipping containers like CryoPort Express Shippers, vacuum insulated dewars, and cryogenic freezer systems to maintain biologic stability during transport.
- Biospecimen Storage & Management: Services for the cryopreservation, archiving, monitoring, and transportation of biological specimens.
- Logistics & Engineering Consulting: Short-term consulting engagements providing logistics support and engineering expertise.
AI Analysis | Feedback
CryoPort (CYRX) primarily sells its services and solutions to other companies within specific life sciences markets.
Based on the provided background, the company serves customers in the following categories:
- Biopharma/Pharma Market
- Animal Health Market
- Human Reproductive Medicine Market
The background information does not provide the names of specific customer companies.
AI Analysis | Feedback
AI Analysis | Feedback
Jerrell W. Shelton President and Chief Executive Officer, Cryoport, Inc.
Jerrell Shelton has over 40 years of executive and corporate governance experience across various industries including information services, software, telecommunications, manufacturing, natural resources, and distribution. He joined Cryoport's board in October 2012 and was appointed President and CEO in November 2012, becoming Chairman in October 2015. Previously, he was a visiting executive at IBM Research, where his team developed WebFountain. He also served as President and CEO of NDC Holdings, Continental Graphics Holdings, Thomson Business Information Group, and Advantage Companies, under his leadership each of those companies achieved rapid revenue growth, improved profitability, and increased shareholder value.
Robert S. Stefanovich Chief Financial Officer and Treasurer, Cryoport, Inc.
Robert Stefanovich has over 30 years of experience in financial management and strategy, with more than 20 years as CFO in the specialty pharma, medical device, and software industries. He previously served as CFO of Novalar Pharmaceuticals, a venture-backed specialty pharmaceutical company. He also held CFO positions at three publicly traded companies: Xcorporeal, Artemis International Solutions Corporation, and Aethlon Medical. Earlier in his career, he was Vice President of Administration at SAIC, a Fortune 500 company, and an audit manager with Price Waterhouse LLP’s technology practice.
Mark W. Sawicki, Ph. D. Chief Scientific Officer, Cryoport, Inc.
Mark Sawicki brings over 20 years of executive and sales management experience, consistently achieving corporate revenue and market share goals in the pharmaceutical and biotechnology industries. He most recently served as the chief business officer at Alcami. Prior to that, he held senior business development roles at AGC Biologics and Curia, where he significantly increased revenue.
Tony Ippolito Vice President, General Counsel and Corporate Secretary, Cryoport, Inc.
Tony Ippolito has over 18 years of experience in mergers and acquisitions, securities law, and general corporate law. Before joining Cryoport, he was a partner in the Corporate and Securities practice group at Snell & Wilmer, LLP, where his practice focused on advising reporting companies in securities law matters, mergers and acquisitions, private placements, and venture capital financings. He is also a former CPA and was a forensic accountant at FTI Consulting, Inc.
Phil Wilson Senior Vice President & Chief Operating Officer, Cryoport Systems
Phil Wilson is an accomplished supply chain executive with over 25 years of industry experience. Before joining Cryoport, he served as Vice President, Supply Chain for Ancillare LP. Prior to that, he was the Director of Global Operational Programs at Catalent Pharma Solutions, where he managed various aspects of the pharmaceutical supply chain.
AI Analysis | Feedback
The key risks to Cryoport's business (CYRX) are:
- Dependence on successful commercialization of cell and gene therapies: Cryoport's revenue growth is heavily reliant on the successful progression of its clients' cell and gene therapies through clinical trials and subsequent commercialization, including Biologics License Application (BLA) and Marketing Authorisation Application (MAA) approvals. Any slowdown in clinical trial activity, delays in regulatory approvals, or lower-than-anticipated commercial adoption of these advanced therapies could significantly impact Cryoport's growth trajectory. The company currently holds a substantial market share in the logistics for cell and gene therapy clinical trials, making its performance closely tied to the success rates within this niche but high-growth sector.
- Intense competition from larger logistics providers: While Cryoport has established a strong position in the specialized and complex logistics for cell and gene therapies, it faces increasing competition, particularly as the industry evolves towards larger-scale commercial distribution, such as for allogeneic therapies. This shift brings Cryoport into direct competition with global logistics giants like DHL, UPS, and FedEx, which possess extensive global networks, greater economies of scale, and the ability to offer competitive pricing or bundled services. Cryoport's more limited presence in the high-volume commercial distribution of mainstream pharmaceuticals, a segment dominated by these larger players, also highlights a competitive weakness.
- Ongoing unprofitability and high financial leverage: Cryoport has consistently reported ongoing losses and negative operating margins, indicating persistent challenges in achieving profitability. While the company has shown improvements in gross margins and narrowed adjusted EBITDA losses, it is not forecasted to become profitable within the next three years. Furthermore, Cryoport carries significant financial leverage, with its net debt/EBITDA ratio notably higher than the market average, and faces a convertible debt maturity in December 2026 which will require refinancing or repayment, potentially straining its cash reserves. The company's Altman Z-Score also suggests a potential risk of financial distress.
AI Analysis | Feedback
AI Analysis | Feedback
CryoPort (NASDAQ: CYRX) operates within several addressable markets related to temperature-controlled logistics and cryopreservation for the life sciences industry.
-
Life Science Logistics Market (Global): The global life science logistics market was calculated at approximately USD 127.7 billion in 2024 and is projected to reach around USD 262.51 billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 7.46% between 2025 and 2034. Another estimate values the global life science logistics market at USD 123.75 billion in 2024, with a projection to grow to USD 289.35 billion by 2035 at a CAGR of 8.03% during the forecast period of 2025–2035. A different source indicates the global life science logistics market size at USD 17.69 billion in 2024, predicted to increase to approximately USD 38.19 billion by 2034, growing at a CAGR of 8.00% from 2025 to 2034.
-
Pharmaceutical Cold Chain Logistics Market (Global): This market was valued at approximately USD 27.9 billion in 2024 and is forecast to reach nearly USD 49.6 billion by 2032, with a CAGR of about 8.5%.
-
Cell and Gene Therapy Cold-Chain Logistics Market (Global): This specialized sector is estimated at USD 1.9 billion in 2024 and is projected to exceed USD 8 billion by 2034, demonstrating a CAGR of about 15.6%. The cell and gene therapy logistics sector is also projected to reach USD 37.8 billion by 2027. The commercial cell and gene therapy (CGT) market is expected to grow from USD 10 billion in 2025 to USD 38 billion by 2030, at a CAGR of approximately 30%. In North America, this market represents roughly 44% of the global total.
-
Cell Cryopreservation Market (Global): The global cell cryopreservation market size is estimated at USD 3.30 billion in 2025 and is projected to reach USD 8.68 billion by 2034, growing at a CAGR of 11.37%. Another report estimates the global cell cryopreservation market size at USD 3.38 billion in 2024, projected to reach USD 8.86 billion by 2033, with a CAGR of 11.40% from 2025 to 2033. A more optimistic projection values the global cell cryopreservation market at USD 11.19 billion in 2024, expected to reach USD 50.88 billion by 2032, growing at a robust CAGR of 21.0%. North America held the largest share of 40.46% of the global market in 2024.
-
Cryopreservation Services Market (Global): This market was estimated to be worth USD 8 billion in 2023 and is expected to increase to USD 34.07 billion by 2030, with a projected CAGR of 23% from 2024 to 2030.
-
Cryopreservation Systems Market (Global): This market, which includes cryogenic vessels and freezers, is estimated at USD 3.9 billion in 2025 and is projected to reach USD 7.1 billion by 2035, growing at a CAGR of 6.2% over the forecast period. The USA market specifically is estimated at USD 1.4 billion in 2025 and is anticipated to reach USD 2.3 billion by 2035.
AI Analysis | Feedback
CryoPort (NASDAQ: CYRX) is positioned for future revenue growth over the next 2-3 years, driven by several key factors:
- Growth in Commercial Cell and Gene Therapy (CGT) Support: CryoPort has demonstrated robust double-digit revenue growth from its commercial cell and gene therapy support services, with a 29% increase year-over-year in 2025. This segment is expected to continue expanding as more advanced therapies gain market acceptance.
- Conversion of Clinical Trials to Commercial Therapies: The company supports a significant number of clinical trials globally, including 86 in Phase 3 and 361 in Phase 2 as of December 31, 2025. This extensive pipeline represents a substantial foundation for future commercial cell and gene therapy revenue streams as these trials progress toward regulatory approval and commercialization.
- Expansion of Global Footprint and Network: CryoPort is strategically expanding its global supply chain network by adding regional depots and biorepositories, including new facilities in Paris, France, and Santa Ana, California. Additionally, strategic partnerships, such as the collaboration with DHL Group, are expected to enhance CryoPort's reach and service capabilities in global growth markets like EMEA and APAC.
- Launch of New Products and Services: The continuous introduction of new products and service enhancements contributes to revenue growth. Recent innovations include the Cryoport Express® Cryogenic HV3 Shipping System, designed to improve patient accessibility and shipping efficiency, and other new offerings like the Fusion® 800 Series cryogenic freezer and IntegriCell™ cryopreservation services.
- Growth in BioStorage and BioServices: The BioStorage and BioServices segment has shown strong momentum, with revenue growing 22% annually in 2025. This area is a key component of the Life Sciences Services business and is anticipated to continue its upward trajectory as demand for specialized biological specimen storage and maintenance increases.
AI Analysis | Feedback
Share Repurchases
- Cryoport initiated a buyback program on August 1, 2024, authorizing the repurchase of up to $200 million of its common stock and/or convertible senior notes through the end of 2027.
- Under this program, the company agreed to repurchase approximately $160 million in aggregate principal amount of its 0.75% Convertible Senior Notes due in 2026 for an aggregate repurchase price of $141.6 million, plus accrued interest, at an 11.5% discount.
- As of December 2, 2025, Cryoport had approximately $65.9 million remaining under its share repurchase authorization.
Outbound Investments
- In 2025, Cryoport divested its CRYOPDP specialty courier business to DHL Group. This divestiture resulted in a net income of $112.3 million from discontinued operations for the fiscal year 2025.
Capital Expenditures
- Cryoport's capital expenditures were $24 million in 2022, $44 million in 2023, and $20 million in 2024.
- The company's capital spending on property, plant, and equipment was $3.45 million in Q4 2025.
- In 2025, Cryoport increased investments into Cryoport Systems to support cell and gene therapy clients. These investments include the launch of a Global Supply Chain Center in Paris, France, the expansion of its Belgian operations, and the consolidation of three facilities in Irvine, California, into one expansive Global Supply Chain Center in Santa Ana, California.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 85.25 |
| Mkt Cap | 4.7 |
| Rev LTM | 680 |
| Op Inc LTM | 18 |
| FCF LTM | 19 |
| FCF 3Y Avg | 71 |
| CFO LTM | 83 |
| CFO 3Y Avg | 104 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 9.7% |
| Rev Chg 3Y Avg | 1.2% |
| Rev Chg Q | 10.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Inc Chg LTM | 11.1% |
| Op Inc Chg 3Y Avg | -4.0% |
| Op Mgn LTM | 1.8% |
| Op Mgn 3Y Avg | -1.9% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 13.7% |
| CFO/Rev 3Y Avg | 9.0% |
| FCF/Rev LTM | 2.5% |
| FCF/Rev 3Y Avg | 4.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 4.7 |
| P/S | 4.3 |
| P/Op Inc | -0.3 |
| P/EBIT | -0.8 |
| P/E | 1.7 |
| P/CFO | 42.4 |
| Total Yield | 0.2% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.8% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.2% |
| 3M Rtn | 17.5% |
| 6M Rtn | -5.1% |
| 12M Rtn | 23.0% |
| 3Y Rtn | 2.1% |
| 1M Excs Rtn | 7.1% |
| 3M Excs Rtn | 7.4% |
| 6M Excs Rtn | -13.0% |
| 12M Excs Rtn | 5.8% |
| 3Y Excs Rtn | -68.9% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Life Sciences Services | 102 | 86 | 150 | 134 | 119 |
| Life Sciences Products | 76 | 72 | 89 | 103 | 104 |
| Elimination of intersegment revenue | -2 | -1 | -6 | ||
| Total | 176 | 157 | 233 | 237 | 223 |
| $ Mil | 2019 |
|---|---|
| Global Bioservices | 0 |
| Global Logistics Solutions | -18 |
| Total | -18 |
| $ Mil | 2019 |
|---|---|
| Global Logistics Solutions | 111 |
| Global Bioservices | 25 |
| Total | 136 |
Price Behavior
| Market Price | $15.49 | |
| Market Cap ($ Bil) | 0.8 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -6.1% | |
| 50 Days | 200 Days | |
| DMA Price | $10.52 | $11.92 |
| DMA Trend | up | up |
| Distance from DMA | 47.2% | 29.9% |
| 3M | 1YR | |
| Volatility | 58.8% | 65.6% |
| Downside Capture | 80.90 | 140.24 |
| Upside Capture | 253.60 | 199.17 |
| Correlation (SPY) | 32.8% | 31.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.46 | 1.50 | 1.36 | 1.62 | 1.64 | 1.65 |
| Up Beta | 0.07 | 1.34 | 0.78 | 1.07 | 1.60 | 1.56 |
| Down Beta | 1.93 | 1.42 | 0.99 | 1.65 | 1.40 | 1.69 |
| Up Capture | 7% | 331% | 333% | 297% | 326% | 381% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 9 | 21 | 35 | 67 | 121 | 349 |
| Down Capture | 6% | 29% | 74% | 128% | 127% | 111% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 12 | 20 | 28 | 56 | 126 | 394 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CYRX | |
|---|---|---|---|---|
| CYRX | 116.9% | 65.4% | 1.43 | - |
| Sector ETF (XLI) | 25.7% | 16.5% | 1.20 | 22.4% |
| Equity (SPY) | 21.7% | 12.5% | 1.29 | 31.4% |
| Gold (GLD) | 23.1% | 27.7% | 0.73 | 8.5% |
| Commodities (DBC) | 21.3% | 18.6% | 0.90 | -10.2% |
| Real Estate (VNQ) | 13.6% | 13.8% | 0.68 | 19.3% |
| Bitcoin (BTCUSD) | -42.0% | 42.7% | -1.15 | 21.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CYRX | |
|---|---|---|---|---|
| CYRX | -24.5% | 77.6% | -0.03 | - |
| Sector ETF (XLI) | 14.1% | 17.6% | 0.63 | 37.5% |
| Equity (SPY) | 13.3% | 17.1% | 0.60 | 42.2% |
| Gold (GLD) | 17.9% | 18.3% | 0.79 | 4.7% |
| Commodities (DBC) | 6.9% | 19.5% | 0.25 | 4.7% |
| Real Estate (VNQ) | 3.1% | 18.9% | 0.06 | 37.9% |
| Bitcoin (BTCUSD) | 12.2% | 53.8% | 0.41 | 22.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CYRX | |
|---|---|---|---|---|
| CYRX | 25.9% | 73.3% | 0.65 | - |
| Sector ETF (XLI) | 14.6% | 20.1% | 0.64 | 27.1% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 33.4% |
| Gold (GLD) | 12.1% | 16.1% | 0.61 | 4.6% |
| Commodities (DBC) | 5.7% | 18.0% | 0.25 | 6.1% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 26.5% |
| Bitcoin (BTCUSD) | 59.0% | 66.2% | 0.99 | 12.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/4/2026 | 19.4% | 29.0% | 61.6% |
| 3/3/2026 | 2.9% | -7.2% | 0.2% |
| 11/4/2025 | -7.5% | -4.0% | 3.5% |
| 8/6/2025 | -6.3% | 3.8% | 18.3% |
| 5/7/2025 | 23.3% | 14.3% | 23.7% |
| 3/4/2025 | 30.6% | 31.4% | 21.7% |
| 11/7/2024 | -3.6% | -8.0% | 3.9% |
| 8/6/2024 | -0.3% | 5.3% | 5.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 13 | 14 |
| # Negative | 13 | 11 | 10 |
| Median Positive | 10.0% | 9.1% | 13.8% |
| Median Negative | -4.9% | -8.0% | -11.3% |
| Max Positive | 30.6% | 39.4% | 61.6% |
| Max Negative | -32.0% | -24.1% | -32.3% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/4/2026 | 19.4% | 29.0% | 61.6% |
| 3/3/2026 | 2.9% | -7.2% | 0.2% |
| 11/4/2025 | -7.5% | -4.0% | 3.5% |
| 8/6/2025 | -6.3% | 3.8% | 18.3% |
| 5/7/2025 | 23.3% | 14.3% | 23.7% |
| 3/4/2025 | 30.6% | 31.4% | 21.7% |
| 11/7/2024 | -3.6% | -8.0% | 3.9% |
| 8/6/2024 | -0.3% | 5.3% | 5.4% |
| 5/7/2024 | -19.5% | -18.0% | -32.3% |
| 3/12/2024 | -11.9% | 1.5% | 10.8% |
| 11/8/2023 | 10.0% | 29.5% | 48.3% |
| 8/9/2023 | -1.8% | -4.6% | -6.4% |
| 5/4/2023 | 13.7% | 3.6% | -6.0% |
| 2/23/2023 | 8.8% | 9.1% | 10.3% |
| 11/3/2022 | -32.0% | -24.1% | -31.3% |
| 8/4/2022 | 6.7% | 18.1% | -16.2% |
| 5/5/2022 | -1.6% | -6.9% | 3.5% |
| 2/24/2022 | 4.4% | 1.6% | -2.7% |
| 11/4/2021 | -2.4% | -9.6% | -21.6% |
| 8/5/2021 | -4.9% | -8.9% | -0.7% |
| 5/4/2021 | 11.6% | 2.4% | -0.1% |
| 3/1/2021 | -5.6% | -22.4% | -20.7% |
| 11/5/2020 | 5.5% | 39.4% | 16.7% |
| 8/7/2020 | -3.4% | -5.2% | 54.9% |
| SUMMARY STATS | |||
| # Positive | 11 | 13 | 14 |
| # Negative | 13 | 11 | 10 |
| Median Positive | 10.0% | 9.1% | 13.8% |
| Median Negative | -4.9% | -8.0% | -11.3% |
| Max Positive | 30.6% | 39.4% | 61.6% |
| Max Negative | -32.0% | -24.1% | -32.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/07/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/13/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/05/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/10/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 03/10/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
| 06/30/2019 | 08/09/2019 | 10-Q |
Recent Forward Guidance
Updated 5/31/2026Latest: Q1 2026 Earnings Reported 5/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 192.00 Mil | 194.00 Mil | 196.00 Mil | 1.0% | Raised | Guidance: 192.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 3/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 190.00 Mil | 192.00 Mil | 194.00 Mil | 11.6% | Higher New | Guidance: 172.00 Mil for 2025 | |
Insider Activity
Updated 6/12/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zecchini, Edward J | Chief Digital and Tech Officer | Direct | Sell | 6122026 | 14.47 | 33,600 | 486,239 | 1,587,788 | Form |
| 2 | Zecchini, Edward J | Chief Digital and Tech Officer | Direct | Sell | 6122026 | 15.23 | 1,400 | 21,324 | 1,671,174 | Form |
| 3 | Mandalam, Ramkumar | Direct | Sell | 6082026 | 15.44 | 23,214 | 358,452 | 1,048,365 | Form | |
| 4 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 6082026 | 16.27 | 169,427 | 2,756,984 | 1,787,523 | Form |
| 5 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 3252026 | 8.18 | 1,094 | 8,949 | 2,284,486 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Zecchini, Edward J | Chief Digital and Tech Officer | Direct | Sell | 6122026 | 14.47 | 33,600 | 486,239 | 1,587,788 | Form |
| 2 | Zecchini, Edward J | Chief Digital and Tech Officer | Direct | Sell | 6122026 | 15.23 | 1,400 | 21,324 | 1,671,174 | Form |
| 3 | Mandalam, Ramkumar | Direct | Sell | 6082026 | 15.44 | 23,214 | 358,452 | 1,048,365 | Form | |
| 4 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 6082026 | 16.27 | 169,427 | 2,756,984 | 1,787,523 | Form |
| 5 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 3252026 | 8.18 | 1,094 | 8,949 | 2,284,486 | Form |
| 6 | Shelton, Jerrell | President, CEO | Direct | Sell | 3252026 | 8.18 | 2,894 | 23,673 | 8,602,145 | Form |
| 7 | Sawicki, Mark W | Chief Scientific Officer | Direct | Sell | 3252026 | 8.18 | 1,341 | 10,969 | 837,272 | Form |
| 8 | Zecchini, Edward J | See Remarks | Direct | Sell | 3172026 | 8.00 | 2,014 | 16,112 | 877,752 | Form |
| 9 | Shelton, Jerrell | President, CEO | Direct | Sell | 3172026 | 8.00 | 7,918 | 63,344 | 8,436,008 | Form |
| 10 | Sawicki, Mark W | Chief Scientific Officer | Direct | Sell | 3172026 | 8.00 | 3,235 | 25,880 | 829,576 | Form |
| 11 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 3162026 | 8.00 | 2,743 | 21,944 | 2,242,968 | Form |
| 12 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 3162026 | 7.76 | 38,700 | 300,386 | 1,984,726 | Form |
| 13 | Mandalam, Ramkumar | Direct | Sell | 12122025 | 9.99 | 11,570 | 115,540 | 806,466 | Form | |
| 14 | Hariri, Robert J | Direct | Sell | 9122025 | 9.71 | 25,000 | 242,738 | 497,855 | Form | |
| 15 | Hariri, Robert J | Direct | Sell | 8292025 | 8.60 | 5,000 | 43,000 | 225,965 | Form | |
| 16 | Stefanovich, Robert | Chief Financial Officer | Direct | Sell | 8212025 | 8.67 | 9,300 | 80,618 | 1,796,247 | Form |
| 17 | Mandalam, Ramkumar | Direct | Sell | 7242025 | 7.24 | 40,728 | 294,899 | 668,519 | Form | |
| 18 | Shelton, Jerrell | President, CEO | Direct | Sell | 6262025 | 7.06 | 16,344 | 115,366 | 6,440,401 | Form |
| 19 | Mandalam, Ramkumar | Direct | Sell | 6262025 | 7.01 | 13,321 | 93,447 | 512,488 | Form | |
| 20 | Shelton, Jerrell | President, CEO | Direct | Sell | 6202025 | 6.47 | 69,135 | 447,525 | 5,906,271 | Form |
| 21 | Shelton, Jerrell | President, CEO | Direct | Sell | 6202025 | 6.81 | 119,281 | 812,542 | 6,215,398 | Form |
| 22 | Shelton, Jerrell | President, CEO | Direct | Sell | 6202025 | 6.81 | 151,304 | 1,029,715 | 6,209,559 | Form |
| 23 | Mandalam, Ramkumar | Direct | Sell | 6132025 | 6.80 | 624 | 4,246 | 451,676 | Form | |
| 24 | Mandalam, Ramkumar | Direct | Sell | 6132025 | 7.01 | 1,895 | 13,286 | 469,764 | Form | |
| 25 | Mandalam, Ramkumar | Direct | Sell | 6132025 | 7.06 | 8,193 | 57,816 | 486,178 | Form | |
| 26 | Zecchini, Edward J | Chief Digital and Tech Officer | Direct | Sell | 6102025 | 6.84 | 51,500 | 352,518 | 618,863 | Form |
| 27 | Mandalam, Ramkumar | Direct | Sell | 6102025 | 7.06 | 5,622 | 39,673 | 543,994 | Form |
Industry Resources
| Industrials Resources |
| IndustryWeek |
| Manufacturing.net |
| Aviation Week |
| Air Freight & Logistics Resources |
| Air Cargo World |
| Logistics Management |
| Journal of Commerce (JOC) |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.